Physicians' Academy for Cardiovascular Education

Analogous to LDL-c, the lower the better also seems true for inflammation

Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

A new challenge for precision medicine: selecting major contributing risk factors

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

After 23 years, CANTOS trial shows that inflammatory hypothesis is right

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

Aug. 28, 2017 - ESC 2017, Barcelona, Spain

Anti-inflammatory therapy that does not affect thrombosis or LDL-c, can beneficially impact arterial disease

Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Aug. 28, 2017

Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk

Aug. 27, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

Aug. 27, 2017

HIV as a model to study effect of chronic inflammation on CV risk

Mar. 16, 2017 - VBWG ACC 2017

Lowering inflammation to address residual CV risk

Mar. 17, 2017 - Dr. Paul M. Ridker - Boston, MA, USA

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Inflammation as potential target for therapy to target residual risk post ACS

Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

Inflammation, the immune system and atherosclerosis

July 7, 2015 - Amsterdam IAS

How to treat residual inflammatory risk?

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Evolving hypotheses on the mechanisms underlying ACS

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60

Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Michelle O'Donoghue

Changing views on mechanisms of atherosclerosis

Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016

Analogous to LDL-c, the lower the better also seems true for inflammation

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - Paul Ridker, Boston, MA, USA
A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but respons to treatment did.

AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but respons to treatment did.

Response to anti-inflammatory treatment explains CV benefit in CANTOS trial

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Paul Ridker (Brigham and Woman’s Hospital, Boston, MA, VS).

Nov. 13, 2017 - news

AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP < 2 mg/L benefitted from a reduction in MACE and mortality, irrespective of the dose of canakinumab.

Targeting IL-1beta to lower inflammation and thereby CV events proved sensible

Oct. 31, 2017 - Peter Libby - J Am Coll Cardiol. 2017

This review summarizes the rationale to specifically target IL-1beta to lower residual inflammatory risk, now shown to be effective in the CANTOS trial. Other potential targets are also discussed.

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Inflammation Expert Opinions Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Inflammation Expert Opinions Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Anti-inflammatory agent favorably modifies vulnerable coronary plaque

Oct. 24, 2017 - Vaidya K et al. - JACC Cardiovasc Imaging. 2017

A year of treatment with low-dose colchicine significantly lowered low attenuation plaque volume and hsCRP levels, as compared with optimal medical treatment in patients with recent ACS.

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Inflammation expert opinions

Aug. 27, 2017
According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Inflammation Expert Opinions According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.

Inflammation Expert Opinions Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.

BET inhibition may lower CV events in high risk CVD patients, suggests hypothesis-generating analysis

Oct. 18, 2017 - Nicholls SJ et al. - Am J Cardiovasc Drugs. 2017

Pooled analysis of phase II studies evaluating apabetalone suggest that this epigenetic therapeutic may yield clinical benefit for CVD patients with low HDL-C, diabetes, and elevated hsCRP levels.

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Inflammation Expert Opinions Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Inflammation expert opinions

Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process.

Inflammation Expert Opinions Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process. Blocking this inflammation may be an additional treatment option beyond lipid lowering for CV risk reduction.

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Inflammation expert opinions

Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation.

Inflammation Expert Opinions Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.